The availability of cardiac myosin inhibitors (CMI) to treat symptomatic left ventricular outflow tract obstruction (LVOTO) and the evolving recommendation
The Zurich Heart House creates and communicates new knowledge in the field of cardiovascular diseases. Through its affiliation with the University of Zurich, the editorial…
Different from other high cardiovascular (CV) risks populations, the evidence supporting the CV protective effect of LDL-C reduction with statins in chronic kidney disease (CKD)…
🙏सुंदर कांड दोहा २८ (अर्थ सहित)🙏जय बजरंग बली🙏जय श्रीराम
AbstractBackground and Aims. The optimal revascularization strategy in patients with ischaemic cardiomyopathy remains unclear with no contemporary randomiz
This week we review a recent thought-provoking work on the topic of the dreaded ‘pre-authorization’ process for procedures being performed in the US. Are there…
Embargoed until 7 a.m. CT/8 a.m. ET, Wednesday, Nov. 6, 2024 DALLAS, Nov. 6, 2024 — Robert A. Harrington, M.D., FAHA, the Stephen and Suzanne…
Join us for the 2025 Stanford Drug Discovery Symposium! SDDS 2025 will be a cornerstone in the drug discovery community for networking and collaboration.
Elevated blood pressure is one of the strongest modifiable risk factors for the prevention of cardiovascular (CV) disease. The ESPRIT (Effects of Intensive Systolic Blood…
Broad and Mass General researcher Alexandra-Chloé Villani and Mass General oncologist Kerry Reynolds describe their pioneering effort to better understand, diagnose, and manage dangerous complications…
